GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InVivo Therapeutics Holdings Corp (OTCPK:NVIVQ) » Definitions » Cyclically Adjusted FCF per Share

InVivo Therapeutics Holdings (InVivo Therapeutics Holdings) Cyclically Adjusted FCF per Share : $-7,586.09 (As of Sep. 2023)


View and export this data going back to 2010. Start your Free Trial

What is InVivo Therapeutics Holdings Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

InVivo Therapeutics Holdings's adjusted free cash flow per share for the three months ended in Sep. 2023 was $-0.735. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-7,586.09 for the trailing ten years ended in Sep. 2023.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 5.40% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 3.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of InVivo Therapeutics Holdings was 5.40% per year. The lowest was -8.40% per year. And the median was 1.00% per year.

As of today (2024-05-03), InVivo Therapeutics Holdings's current stock price is $0.37. InVivo Therapeutics Holdings's Cyclically Adjusted FCF per Share for the quarter that ended in Sep. 2023 was $-7,586.09. InVivo Therapeutics Holdings's Cyclically Adjusted Price-to-FCF of today is .


InVivo Therapeutics Holdings Cyclically Adjusted FCF per Share Historical Data

The historical data trend for InVivo Therapeutics Holdings's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InVivo Therapeutics Holdings Cyclically Adjusted FCF per Share Chart

InVivo Therapeutics Holdings Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -10,606.40 -10,354.50 -9,975.90 -9,724.56 -8,759.50

InVivo Therapeutics Holdings Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -9,317.52 -8,759.50 -8,509.08 -8,058.51 -7,586.09

Competitive Comparison of InVivo Therapeutics Holdings's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, InVivo Therapeutics Holdings's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InVivo Therapeutics Holdings's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InVivo Therapeutics Holdings's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where InVivo Therapeutics Holdings's Cyclically Adjusted Price-to-FCF falls into.



InVivo Therapeutics Holdings Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, InVivo Therapeutics Holdings's adjusted Free Cash Flow per Share data for the three months ended in Sep. 2023 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=-0.735/129.8595*129.8595
=-0.735

Current CPI (Sep. 2023) = 129.8595.

InVivo Therapeutics Holdings Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201312 -4,288.000 98.326 -5,663.183
201403 -4,229.000 99.695 -5,508.587
201406 -3,621.000 100.560 -4,676.050
201409 -3,229.000 100.428 -4,175.301
201412 -4,252.000 99.070 -5,573.476
201503 -2,913.000 99.621 -3,797.195
201506 -4,234.000 100.684 -5,460.904
201509 -3,826.000 100.392 -4,949.049
201512 -5,356.000 99.792 -6,969.744
201603 -2,103.500 100.470 -2,718.805
201606 -2,024.000 101.688 -2,584.724
201609 -2,180.000 101.861 -2,779.216
201612 -2,116.000 101.863 -2,697.579
201703 -3,078.000 102.862 -3,885.854
201706 -2,438.500 103.349 -3,064.007
201709 -2,301.500 104.136 -2,870.024
201712 -2,056.000 104.011 -2,566.948
201803 -1,846.500 105.290 -2,277.393
201806 -1,539.500 106.317 -1,880.406
201809 -255.300 106.507 -311.277
201812 -248.917 105.998 -304.952
201903 -279.833 107.251 -338.823
201906 -275.417 108.070 -330.949
201909 -146.833 108.329 -176.016
201912 -118.063 108.420 -141.409
202003 -95.436 108.902 -113.803
202006 -11.039 108.767 -13.180
202009 -9.872 109.815 -11.674
202012 -2.034 109.897 -2.403
202103 -2.744 111.754 -3.189
202106 -1.243 114.631 -1.408
202109 -1.389 115.734 -1.559
202112 -1.370 117.630 -1.512
202203 -2.814 121.301 -3.013
202206 -1.553 125.017 -1.613
202209 -1.748 125.227 -1.813
202212 -1.104 125.222 -1.145
202303 -1.179 127.348 -1.202
202306 -0.791 128.729 -0.798
202309 -0.735 129.860 -0.735

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


InVivo Therapeutics Holdings  (OTCPK:NVIVQ) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


InVivo Therapeutics Holdings Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of InVivo Therapeutics Holdings's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


InVivo Therapeutics Holdings (InVivo Therapeutics Holdings) Business Description

Traded in Other Exchanges
Address
One Kendall Square, Suite B14402, Building 1400 West, 4th Floor, Cambridge, MA, USA, 02139
InVivo Therapeutics Holdings Corp is a research and clinical stage biomaterials and biotechnology company. It focuses on the treatment of spinal cord injury. The company's product pipeline consists of Neuro spinal scaffold and Bioengineered neural trails. The firm has a clinical development program for acute spinal cord injury and a preclinical development program for chronic spinal cord injury.
Executives
Brice Foose 10 percent owner 236 SILENT MEADOW DRIVE, LAKE ST. LOUIS MO 63367
Daniel R Marshak director C/O CAMBREX CORP, ONE MEADOWLANDS PLZ, EAST RUTHERFORD NJ 07073
Christina Morrison director ARAMARK, 1101 MARKET STREET, PHILADELPHIA PA 19107
Richard M. Toselli director, officer: CEO and CMO C/O INVIVO THERAPEUTICS HOLDINGS CORP., 1 KENDALL SQUARE, SUITE B14402, CAMBRIDGE MA 02139
Richard Christopher officer: Chief Financial Officer C/O LUCID, INC., 50 METHODIST HILL DR, SUITE 1000, ROCHESTER NY 14623
C Ann Merrifield director
Bob Rosenthal director 20 NEWBURY ST, BOSTON MA 02116
Heather Hamel officer: Chief Legal Officer and GC ONE KENDALL SQUARE, BUILDING 1400 WEST, FLOOR 4, CAMBRIDGE MA 02139
Jeffrey Modestino officer: See Remarks C/O INVIVO THERAPEUTICS HOLDINGS CORP., 1 KENDALL SQUARE, SUITE B14403, CAMBRIDGE MA 02139
Christopher Mcnulty officer: Chief Financial Officer C/O INVIVO THERAPEUTICS HOLDINGS CORP., 1 KENDALL SQUARE, SUITE B14402, CAMBRIDGE MA 02139
Melanie Golarz officer: Interim CFO C/O INVIVO THERAPEUTICS HOLDINGS CORP., 1 KENDALL SQUARE, SUITE B14402, CAMBRIDGE MA 02139
Jeffrey S. Hatfield director 11080 ROSELLE STREET, SAN DIEGO CA 92121
Pamela J Stahl officer: Chief Commercial Officer ONE KENDALL SQUARE, SUITE B14402, CAMBRIDGE MA 02139
Richard John Roberts director ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Masuoka K. Lorianne officer: Chief Medical Officer C/O NEKTAR THERAPEUTICS, 201 INDUSTRIAL ROAD, SAN CARLOS CA 94070

InVivo Therapeutics Holdings (InVivo Therapeutics Holdings) Headlines

From GuruFocus